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Background
DNA hypermethylation and histone deacetylation are epi-
genetic events that contribute to the absence or downreg-
ulated expression of different components of the tumor
recognition complex. These events affect the processing
and presentation of antigenic peptides to CTLs by HLA
class I molecules. In this work we evaluated the effect of
the DNA hypomethylating agent hydralazine (H) and the
histone deacetylase inhibitor valproic acid (VA), on the
expression of HLA class I molecules and in the antigen-
specific immune recognition of cervical cancer cells.
Materials and methods
Cell lines C33A (HPV-), CaSki (HPV-16+) and MS751
(HPV-18+) were treated with hydralazine and valproic
acid to assess cell proliferation and to evaluate the expres-
sion of HLA class I molecules on cell surface by flow
cytometry. Primary cervical tumors of five HLA-A*0201
allele patients were typed for HPV and their CTLs stimu-
lated in vitro with the T2 cell line previously loaded with
50 μM of the HPV peptides. Cytotoxicity of stimulated
CTLs was assayed against Caski and MS751 cells pre-
treated with hydralazine and valproic acid.
Results
The combination of HV acid had antiproliferative effect in
C33 and CasKi cells. VA and VA+H up-regulated the con-
stitutive HLA class I expression as evaluated by flow
cytometry. In addition, the antigenic immune recognition
of CaSki and MS751 cells by CTLs specific to HPV-16/18
E6 and E7-derived epitopes, was more prominent on cells
treated with VA or H+VA than cells treated with either H
or IFN-γ.
Conclusion
These results support the potential use of H and VA as an
adjunt for immune intervention in cervical cancer patients
whenever clinical protocols based on tumor antigen rec-
ognition is desirable, such as in those cases where the
application of E6 and E7 based therapeutic vaccines is
used.
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